Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)
Clinical trial NCT01691248 · COMPLETED
Trial details
- NCT number
- NCT01691248
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-10-10
- Primary completion
- 2015-03-18
- Enrollment
- 611
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.